Galapagos NV – December 2018

The Belgian company Galapagos NV headquartered in Mechelen is a biotech company in the field of active ingredient research. Galapagos NV specializes in the discovery and development of small molecule medicines (with a focus on particularly small molecules with novel modes of action). Galapagos NV’s current development pipeline includes projects in phase 3, 2, 1, pre-clinical studies and discovery programs for medicines for the treatment of cystic fibrosis, inflammations, fibrosis, osteoarthritis, and other symptoms.

Galapagos NV’s innovative activities are orientated towards the research of new modes of action, based on which new medicines are then developed. Galapagos NV’s development pipeline represents one of the largest development pipelines in the biotech industry and comprises developments in phase 3 (e.g. filgotinib), 2, phase 1, pre-clinical studies, as well as more than 20 discovery programs. To achieve this goal, Galapagos NV focuses strongly on strategic collaborations, e.g. with Novartis, MorphoSys, Servier, as well as Gilead. Among the innovative results of Galapagos NV’s research and development activities deserving particular mention is filgotinib. It is currently being considered for the treatment of rheumatoid arthritis (RA) and Crohn’s disease. In light of increasing standards of healthcare worldwide, Galapagos NV with its innovative developments and well-filled development pipelines is therefore active in a field of increasing importance.